Chemistry:Galiximab
From HandWiki
Short description: Monoclonal antibody
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Chimeric (primate/human) |
| Target | CD80 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
  (what is this?) (verify) | |
Galiximab is a monoclonal antibody designed for the treatment of B-cell lymphoma.[1] (As of September 2009), it is undergoing Phase III clinical trials.[2] The drug is a chimeric antibody from Macaca irus and Homo sapiens.[3]
References
- ↑ "Immunopathology and Immunotherapy of Non-Hodgkin Lymphoma". Cancer immunology: cancer immunotherapy for organ-specific tumors (Second ed.). Cham: Springer Nature. 2020. p. 178. ISBN 978-3-03-057949-4. https://books.google.com/books?id=v5AOEAAAQBAJ&dq=Galiximab&pg=PA178.
- ↑ "Biogen Idec: Pipeline". http://www.biogenidec.com/site/pipeline.html.
- ↑ WHO Drug Information
External links
 |  |
